Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report - Summary - MDSpire

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

  • By

  • Anaya Dewey

  • Joaquina C. Baranda

  • Wei Zhang

  • Mohammad Haeri

  • Brian Milligan

  • Tolga Tuncer

  • May 28, 2026

  • 0 min

Share

Objective:

To examine the molecular profile of a glioblastoma case with a rare MEF2D-NTRK1 gene fusion.

Key Findings:
  • The patient exhibited a rare MEF2D-NTRK1 gene fusion in glioblastoma.
  • The tumor was IDH-wildtype with an unmethylated MGMT promoter.
Interpretation:

Limitations:
  • Limited data on the efficacy of repotrectinib combined with bevacizumab.
  • Challenges in differentiating between pseudoprogression and true progression post-chemoradiation.
Conclusion:

Original Source(s)

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

  • by Anaya Dewey, Joaquina C. Baranda, Wei Zhang, Mohammad Haeri, Brian Milligan, Tolga Tuncer

  • May 28, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review